NewcelX prices $1.4 million private placement at 20% premium
The Zurich-based biopharmaceutical company will sell shares and warrants to fund its lead type 1 diabetes program after a recent FDA Pre-IND meeting.
NewcelX Ltd. (Nasdaq: NCEL) announced on July 31, 2026 that it had priced a private placement of common shares at $4.033 apiece, a level the company said represents a 20% premium to the last closing price of the Company's common shares on July 30, 20261.
Under the deal terms, NewcelX is selling an aggregate of 347,134 common shares along with warrants to purchase another 347,134 common shares, with the warrants carrying an exercise price of $4.437, equal to 132% of the July 30 closing price1. The company said the offering includes participation from existing shareholders and is expected to close on or about August 14, 2026, subject to customary closing conditions1.
NewcelX said it plans to direct the proceeds, combined with cash on hand and a previously disclosed $25 million equity line, primarily to advance NCEL-101, its lead program for type 1 diabetes being developed in collaboration with Eledon Pharmaceuticals, along with working capital and general corporate purposes1.
CEO and Executive Chairman Ronen Twito linked the financing to recent regulatory progress, saying the company had recent achievements, including the successful FDA Pre-IND meeting for NCEL-1011, and stated the new funds would help advance NCEL-101 toward IND-enabling studies1.
The securities are being sold under a private placement exemption, and the shares and warrants have not been registered under the Securities Act of 1933 and are being offered under Section 4(a)(2) and Regulation D1. The company noted that more detail on risks facing NewcelX appears in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.